Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$26.63
0.110.41%
At close: -
$26.63
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Vera Therapeutics Analyst Ratings and Price Targets | NASDAQ:VERA | Benzinga
Vera Therapeutics Inc has a consensus price target of $50.58 based on the ratings of 12 analysts. The high is $107 issued by Cantor Fitzgerald on October 3, 2024. The low is $6 issued by Jefferies on January 4, 2023. The 3 most-recent analyst ratings were released by JP Morgan, Guggenheim, and Wolfe Research on March 4, 2025, February 27, 2025, and February 4, 2025, respectively. With an average price target of $60.33 between JP Morgan, Guggenheim, and Wolfe Research, there's an implied 126.56% upside for Vera Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Guggenheim
Wolfe Research
Wells Fargo
Wedbush
1calculated from analyst ratings
Analyst Ratings for Vera Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/04/2025 | Buy Now | 166.62% | JP Morgan | Anupam Rama59% | $77 → $71 | Maintains | Overweight | Get Alert |
| 02/27/2025 | Buy Now | 129.06% | Guggenheim | Vamil Divan75% | $59 → $61 | Maintains | Buy | Get Alert |
| 02/04/2025 | Buy Now | 84% | Wolfe Research | Andy Chen37% | → $49 | Initiates | → Outperform | Get Alert |
| 11/21/2024 | Buy Now | 162.86% | Wells Fargo | Mohit Bansal72% | → $70 | Initiates | → Overweight | Get Alert |
| 11/08/2024 | Buy Now | 42.7% | Wedbush | Laura Chico47% | $30 → $38 | Maintains | Neutral | Get Alert |
| 11/05/2024 | Buy Now | 181.64% | JP Morgan | Anupam Rama59% | $72 → $75 | Maintains | Overweight | Get Alert |
| 10/28/2024 | Buy Now | 140.33% | Guggenheim | Vamil Divan75% | $56 → $64 | Maintains | Buy | Get Alert |
| 10/16/2024 | Buy Now | 125.31% | Scotiabank | Greg Harrison51% | → $60 | Initiates | → Sector Outperform | Get Alert |
| 10/03/2024 | Buy Now | 301.8% | Cantor Fitzgerald | Pete Stavropoulos42% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 10/01/2024 | Buy Now | 301.8% | Cantor Fitzgerald | Pete Stavropoulos42% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 09/23/2024 | Buy Now | 301.8% | Cantor Fitzgerald | Pete Stavropoulos42% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 301.8% | Cantor Fitzgerald | Pete Stavropoulos42% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 301.8% | Cantor Fitzgerald | Pete Stavropoulos42% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 09/06/2024 | Buy Now | 301.8% | Cantor Fitzgerald | Pete Stavropoulos42% | $107 → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 09/03/2024 | Buy Now | 170.37% | JP Morgan | Anupam Rama59% | $62 → $72 | Maintains | Overweight | Get Alert |
| 08/13/2024 | Buy Now | 132.82% | JP Morgan | Anupam Rama59% | $65 → $62 | Maintains | Overweight | Get Alert |
| 05/31/2024 | Buy Now | 144.09% | JP Morgan | Anupam Rama59% | $60 → $65 | Maintains | Overweight | Get Alert |
| 05/10/2024 | Buy Now | 155.35% | Raymond James | Steven Seedhouse58% | $57 → $68 | Maintains | Strong Buy | Get Alert |
| 04/05/2024 | Buy Now | 110.29% | Guggenheim | Vamil Divan75% | $56 → $56 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 110.29% | Guggenheim | Vamil Divan75% | $27 → $56 | Maintains | Buy | Get Alert |
| 03/21/2024 | Buy Now | 27.68% | Wedbush | Laura Chico47% | $21 → $34 | Maintains | Neutral | Get Alert |
| 01/26/2024 | Buy Now | -21.14% | Wedbush | Laura Chico47% | $16 → $21 | Maintains | Neutral | Get Alert |
| 01/26/2024 | Buy Now | 38.94% | Raymond James | Steven Seedhouse58% | $29 → $37 | Upgrade | Outperform → Strong Buy | Get Alert |
| 01/25/2024 | Buy Now | -2.37% | Oppenheimer | Justin Kim37% | → $26 | Initiates | → Outperform | Get Alert |
| 01/08/2024 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos42% | — | Initiates | → Overweight | Get Alert |
| 12/27/2023 | Buy Now | -6.12% | HC Wainwright & Co. | Ed Arce60% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2023 | Buy Now | 8.9% | Raymond James | Steven Seedhouse58% | → $29 | Initiates | → Outperform | Get Alert |
| 11/30/2023 | Buy Now | -17.39% | JP Morgan | Anupam Rama59% | $25 → $22 | Maintains | Overweight | Get Alert |
| 11/10/2023 | Buy Now | -2.37% | Jefferies | Farzin Haque57% | $18 → $26 | Upgrade | Hold → Buy | Get Alert |
| 09/26/2023 | Buy Now | -6.12% | HC Wainwright & Co. | Ed Arce60% | $10 → $25 | Maintains | Buy | Get Alert |
| 08/16/2023 | Buy Now | 1.39% | Guggenheim | Vamil Divan75% | → $27 | Initiates | → Buy | Get Alert |
| 08/11/2023 | Buy Now | -39.92% | Wedbush | Laura Chico47% | $12 → $16 | Maintains | Neutral | Get Alert |
| 06/08/2023 | Buy Now | -62.45% | HC Wainwright & Co. | Ed Arce60% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | -62.45% | HC Wainwright & Co. | Ed Arce60% | $11 → $10 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | -66.2% | Wedbush | Laura Chico47% | $6 → $9 | Maintains | Neutral | Get Alert |
| 04/12/2023 | Buy Now | -17.39% | JP Morgan | Anupam Rama59% | $38 → $22 | Maintains | Overweight | Get Alert |
| 03/29/2023 | Buy Now | -58.69% | HC Wainwright & Co. | Ed Arce60% | $15 → $11 | Maintains | Buy | Get Alert |
| 01/04/2023 | Buy Now | -77.47% | Jefferies | Maury Raycroft31% | $32 → $6 | Downgrade | Buy → Hold | Get Alert |
| 01/04/2023 | Buy Now | -69.96% | Wedbush | Laura Chico47% | → $8 | Downgrade | Outperform → Neutral | Get Alert |
| 01/04/2023 | Buy Now | -43.67% | HC Wainwright & Co. | Ed Arce60% | $36 → $15 | Maintains | Buy | Get Alert |
| 11/18/2022 | Buy Now | 42.7% | JP Morgan | Anupam Rama59% | $35 → $38 | Maintains | Overweight | Get Alert |
| 08/22/2022 | Buy Now | 35.19% | HC Wainwright & Co. | Ed Arce60% | $35 → $36 | Maintains | Buy | Get Alert |
| 07/12/2022 | Buy Now | 31.43% | JP Morgan | Anupam Rama59% | → $35 | Initiates | → Overweight | Get Alert |
| 05/02/2022 | Buy Now | 31.43% | HC Wainwright & Co. | Ed Arce60% | → $35 | Initiates | → Buy | Get Alert |
| 04/19/2022 | Buy Now | 20.17% | Wedbush | Laura Chico47% | → $32 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Vera Therapeutics (VERA) stock?
The latest price target for Vera Therapeutics (NASDAQ:VERA) was reported by JP Morgan on March 4, 2025. The analyst firm set a price target for $71.00 expecting VERA to rise to within 12 months (a possible 166.62% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vera Therapeutics (VERA)?
The latest analyst rating for Vera Therapeutics (NASDAQ:VERA) was provided by JP Morgan, and Vera Therapeutics maintained their overweight rating.
When was the last upgrade for Vera Therapeutics (VERA)?
The last upgrade for Vera Therapeutics Inc happened on January 26, 2024 when Raymond James raised their price target to $37. Raymond James previously had an outperform for Vera Therapeutics Inc.
When was the last downgrade for Vera Therapeutics (VERA)?
The last downgrade for Vera Therapeutics Inc happened on January 4, 2023 when Jefferies changed their price target from $32 to $6 for Vera Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Vera Therapeutics (VERA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vera Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vera Therapeutics was filed on March 4, 2025 so you should expect the next rating to be made available sometime around March 4, 2026.
Is the Analyst Rating Vera Therapeutics (VERA) correct?
While ratings are subjective and will change, the latest Vera Therapeutics (VERA) rating was a maintained with a price target of $77.00 to $71.00. The current price Vera Therapeutics (VERA) is trading at is $26.63, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.